EntreMed Presents Initial Clinical Results for...( Orphan Drug Designation and Canadian ...),Health

Orphan Drug Designation and Canadian CTA Accelerate ENMD-2076 Program Momentum

ROCKVILLE, Md., Feb. 9 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced recent developments in its program for ENMD-2076, an Aurora A/angiogenic kinase inhibitor. These developments include the presentation of initial results for a Phase 1 study in patients with refractory solid tumors as well as preclinical data showing significant potential for the use of ENMD-2076 in combination with platinum-based chemotherapy in breast cancer. In addition, EntreMed has received an Orphan Drug Designation from the FDA for the treatment of multiple myeloma using ENMD-2076. To further enhance its clinical development efforts for the drug candidate, a No Objection Letter was received by EntreMed from Health Canada permitting ENMD-2076 to be used in clinical trials within Canada. Data for the Phase 1 study in solid tumors, which is being conducted at the University of Colorado Cancer Center and the Dana-Farber Cancer Institute, were presented by Jennifer Diamond, M.D., during an oral presentation at the 11th International Symposium on Anti-Angiogenic Agents held last week in San Diego, California. Dr. Diamond is a Hematology/Oncology Fellow, working in the Developmental Therapeutics Program of the University of Colorado.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Results from the ongoing Phase 1 study in patients with refractory solid tumors demonstrated that ENMD-2076 administered orally in 28-day cycles was well tolerated. Data show preliminary evidence of antitumor activity as determ
'/>"/>